l.rahimi96/100
Declared figure not adjusted upward between certificate and commercial documentation. Nothing unsecured in the consignment. Not medical advice.
WWB — Wuhan Wansheng Biotechnology Co., Ltd.
Wuhan, CN. The index holds 398 assay reports across 66 batches and 26 compounds, contributed by 6 laboratories. Every figure below is computed from those records and from nothing else.
Where WWB sells
Wuhan Wansheng Biotechnology Co., Ltd. sells from its own storefront. The link is marked nofollow and sponsored: it exists so the figures on this scorecard can be read against what the supplier itself publishes. The index is paid nothing for it and a link is not an assessment.
Visit WWB at wuhanwanshengbio.com →
Every figure above describes lots the index has seen. It says nothing about the lot you are offered, and the only check that does is the one on the certificate against the vial.
Block 1
Identification
Business facts, held constant across the index and not derived from the data. The index sells nothing and takes no supplier payment for placement; the storefront link below is marked nofollow and sponsored so a record can be checked against the seller, and is not a recommendation.
- Legal name
- Wuhan Wansheng Biotechnology Co., Ltd.
- Short code in this index
- WWB
- Also known as
- WWB · Wansheng Bio · WWBT
- Domain
- wuhanwanshengbio.com →
- City
- Wuhan
- Region
- Hubei
- Country
- CN
- Established
- not stated
- First record in index
- 17 Jan 2024
- Most recent record
- 14 Oct 2026
Block 1b
Dispatch and regional stock
Counted from the chain-of-custody line on this supplier's own records, which names the route each vial travelled to the laboratory, and from the on-record reviews below. The index has no sight of any supplier's warehouse network and publishes none.
Domestic-warehouse route
16.6%
n=398
Retail, shipped to the buyer
77.1%
n=398
Direct to the laboratory
0.0%
n=398
Median courier leg, direct despatch
no such consignment
| Route to the laboratory | Records | Share |
|---|---|---|
| Domestic warehouse despatch | 66 | 16.6% |
| Retail purchase, shipped to the buyer | 233 | 58.5% |
| Retail purchase via a third-party forwarder | 74 | 18.6% |
| Laboratory retained-sample archive | 25 | 6.3% |
Every record here carries a chain-of-custody line and that line names the route the vial travelled. Of the 398 WWB records the index holds, 66 reached the contributing laboratory from a domestic warehouse rather than as a cross-border consignment, covering 17 of the 26 compounds WWB is represented by here — Semaglutide, Tirzepatide, Liraglutide, BPC-157, GHK-Cu, Retatrutide and 11 further compounds. Those are the WWB lines this index has actually seen arrive from regional stock, and they are a count of consignments rather than a stock listing: a line missing from them may simply never have been submitted for assay.
One contributor on the record below documents WWB stock held in Germany, with a transit of 4 working days against a quoted 4. Germany is the only regional stock location named anywhere in WWB's record here, and one consignment described by one buyer is exactly that. It is not a warehouse list and the index has not verified it.
The index measures nothing about lead time — it assays material, it does not buy it. What it has is WWB's own reviewers: 5 of the 26 on-record reviews state a quoted window and what happened against it, and 1 of them describes same-day dispatch. The reviews are reproduced in full in Block 11.
Block 2
Headline statistics
Each figure carries the n it was computed from. The n= badge next to a statistic is the number of records it was computed from. Below n=8 the badge is amber. Below n=3 the statistic is suppressed and the individual values are shown instead.
Median purity
99.37%
n=398
Interquartile range
0.62pp
n=398
10th percentile
98.84%
n=398
Pass rate vs index spec
100.0%
n=398
Median recovery vs claim
98.9%
n=224
Median water
4.62%
n=398
Median |mass error|
2.5ppm
n=345
Records carrying a flag
26.1%
n=398
Block 3
Reproducibility across independent tests of one lot
Where the same physical lot was assayed more than once, the spread between those results is a property of the material and the fill, not of the market. It is the rarest and most informative statistic on this page, and it exists only for lots someone tested twice.
Median within-batch spread
0.69pp
n=46
Index median spread
0.67pp
n=28
Lots tested 3+ times
46
n=66
Across the 46 WWB lots in the index with three or more independent assays, the median spread between the highest and lowest purity result on one lot is 0.69 pp. Interpreting that number requires the laboratory repeatability figures: the best contributing laboratory here repeats to 0.16 pp and the worst to 0.34 pp, so a within-lot spread under about 0.5 pp is indistinguishable from measurement noise and a spread above 1 pp is a statement about the material.
Block 4
Supplier certificate against independent measurement
The supplier's own COA purity figure for a lot, minus the median of the index's independent observations of the same physical lot. Positive means the certificate reads higher than the measurement. Rule AX-R05 fires above 1.5 pp.
Median COA divergence
0.00pp
n=66
Index median divergence
+0.06pp
n=28
Divergences in the supplier's favour
47%
n=66
Divergences beyond 1 pp
0%
n=66
Block 5
Provenance — where the tested material came from
Supplier-supplied samples are weaker evidence than independently purchased ones, because the supplier chose the vial. The index measures the size of that effect rather than assuming it.
Buyer-sourced median
99.36%
n=373
Supplier-supplied median
suppressed
n=0
n<3 — see individual records
Supplier-supplied share of records
0.0%
n=398
Too few records in one or both provenance classes (buyer-sourced n=373, supplier-supplied n=0) to compute a provenance gap for WWB. The index-wide effect is +0.31 pp and applies until measured otherwise.
Block 6
Documentation completeness
The score is not an opinion about paperwork. Each component is the share of WWB batches in the index whose certificate carries that field, weighted as set out on the scoring rubric.
Documentation score
92/100
n=66
Index median score
85/100
n=28
| Certificate field | Batches carrying it | Rubric weight | |
|---|---|---|---|
| Purity figure stated | 100% | 25 points | |
| Analytical method stated (column, gradient, wavelength) | 70% | 25 points | |
| Peptide content stated | 71% | 20 points | |
| Endotoxin stated | 32% | 15 points | |
| Named impurities rather than a total | 71% | 15 points |
Block 7
Coverage by compound
The delta column is this supplier's median minus the index-wide median for the same compound, which is the only comparison worth making: comparing a supplier's aggregate against another supplier's aggregate compares their product mixes as much as their process control.
| Compound | Class | Reports | Median % | Index median % | Δ (pp) | Index spec | Pass % |
|---|---|---|---|---|---|---|---|
| Semaglutide | Incretin | 111 | 99.24 | 98.89 | +0.35 | 97.0 | 100 |
| Tirzepatide | Incretin | 43 | 99.00 | 98.55 | +0.45 | 97.0 | 100 |
| CJC-1295 with DAC | Growth-hormone | 26 | 99.61 | 98.95 | +0.66 | 97.5 | 100 |
| Retatrutide | Incretin | 22 | 99.20 | 98.37 | +0.83 | 96.5 | 100 |
| Liraglutide | Incretin | 19 | 99.34 | 99.00 | +0.34 | 97.5 | 100 |
| Ipamorelin | Growth-hormone | 19 | 99.83 | 99.47 | +0.36 | 99.0 | 100 |
| Semax | Neuroactive | 14 | 99.48 | 99.46 | +0.02 | 98.5 | 100 |
| Thymulin | Tissue-repair | 13 | 99.23 | 99.27 | -0.04 | 98.0 | 100 |
| Survodutide | Incretin | 13 | 98.96 | 98.38 | +0.58 | 96.5 | 100 |
| Kisspeptin-10 | Melanocortin-receptor | 13 | 99.92 | 99.28 | +0.64 | 98.5 | 100 |
| BPC-157 | Tissue-repair | 12 | 99.75 | 99.16 | +0.59 | 98.0 | 100 |
| MOTS-c | Metabolic | 12 | 99.75 | 99.13 | +0.62 | 98.0 | 100 |
| ARA-290 | Tissue-repair | 10 | 99.91 | 99.42 | +0.49 | 98.0 | 100 |
| IGF-1 LR3 | Growth-hormone | 10 | 99.19 | 98.28 | +0.91 | 95.0 | 100 |
| NAD+ | Non-peptide | 9 | 99.47 | 99.28 | +0.19 | 97.0 | 100 |
| Desmopressin | Hypothalamic | 8 | 99.56 | 98.83 | +0.73 | 98.5 | 100 |
| GHK-Cu | Tissue-repair | 7 n=7 | 99.43 | 98.56 | +0.87 | 97.0 | 100 |
| L-Glutathione (reduced) | Short | 7 n=7 | 99.36 | 99.33 | +0.03 | 98.5 | 100 |
| TB-500 | Tissue-repair | 7 n=7 | 99.81 | 99.53 | +0.28 | 98.5 | 100 |
| Melanotan II | Melanocortin-receptor | 7 n=7 | 99.54 | 99.42 | +0.12 | 98.5 | 100 |
| Afamelanotide | Melanocortin-receptor | 7 n=7 | 99.42 | 99.06 | +0.36 | 98.0 | 100 |
| Dihexa | Neuroactive | 3 n=3 | 99.79 | 99.63 | +0.17 | 98.5 | 100 |
| GHRP-6 | Growth-hormone | 3 n=3 | 99.73 | 99.54 | +0.19 | 99.0 | 100 |
| Epitalon | Short | 1 n=1 | n<3 | 99.56 | — | 99.0 | 100 |
| Mazdutide | Incretin | 1 n=1 | n<3 | 98.14 | — | 96.5 | 100 |
| KPV | Tissue-repair | 1 n=1 | n<3 | 99.64 | — | 99.0 | 100 |
Full per-compound breakdown with distributions and caveats →
Block 8
Quarterly trend
Submission volume is not market share and a quarterly median is not a trend unless the compound mix held still. Both caveats apply to every row below.
Median purity by quarter
Quarters with fewer than two purity records are gaps in the line rather than zeroes.
Coverage growth
Records added per quarter. Growth here is index coverage, not supplier volume.
| Quarter | Batches | Reports | Median purity | Range | Flagged |
|---|---|---|---|---|---|
| 2024-Q1 | 3 | 32 | 99.50 | 98.73–99.93 | 4 |
| 2024-Q2 | 2 | 14 | 99.93 | 99.34–99.93 | 0 |
| 2024-Q3 | 4 | 27 | 99.07 | 97.95–99.93 | 6 |
| 2024-Q4 | 4 | 38 | 99.33 | 98.39–99.93 | 13 |
| 2025-Q1 | 10 | 63 | 99.23 | 98.04–99.93 | 28 |
| 2025-Q2 | 3 | 6 | 99.36 | 99.26–99.73 | 1 |
| 2025-Q3 | 5 | 16 | 99.66 | 99.31–99.93 | 2 |
| 2025-Q4 | 6 | 38 | 99.28 | 98.63–99.93 | 5 |
| 2026-Q1 | 13 | 63 | 99.59 | 98.05–99.93 | 3 |
| 2026-Q2 | 13 | 78 | 99.39 | 98.37–99.93 | 34 |
| 2026-Q3 | 3 | 23 | 99.28 | 98.56–99.75 | 8 |
Block 9
Which laboratory produced these numbers
Laboratories disagree with each other by a measured amount. A supplier tested mostly by one laboratory carries that laboratory's offset in its aggregate, and the adjusted column removes it.
| Laboratory | Reports | Median purity | Lab bias (pp) | Bias-adjusted |
|---|---|---|---|---|
| Janoshik | 177 | 99.39 | +0.00 | 99.39 |
| PeptideMeter | 72 | 99.30 | -0.05 | 99.34 |
| Medutest | 53 | 99.39 | +0.08 | 99.31 |
| VendorInvestigate | 39 | 99.33 | -0.11 | 99.44 |
| Nordanalyt | 34 | 99.30 | +0.02 | 99.28 |
| Kestrel | 23 | 99.93 | +0.24 | 99.69 |
Bias figures are estimated from paired same-lot comparisons and are published with their confidence intervals on inter-lab agreement.
Block 10
What this data does and does not show
Block 11
On-the-record reviews 26
Reviews are signed statements from index contributors about their own testing of this supplier's material. They are opinions attached to evidence, and they are not used in any statistic on this page.
98.0/ 100975 ratings across the index network
s.nilsen100/100
Dispatch inside the quoted window on all four orders. Tracking record corresponded to consignment position at every hop.
z.kowalski98/100
Transit 4 days from stock held in Germany against a quoted 4. Customs documentation correct at first presentation. Desiccant enclosed within the secondary container.
re.chukwu97/100
Direct-supply material 98.6%. Intermediary vial, same nominal description, 98.2%.
s.bakker97/100
Consistency: 11 lots, purity band under 1.0 points wide.
ka.roos96/100
Custom synthesis delivered 2 days inside the quoted schedule at the specified purity. Medutest report held on file, figures match published.
m.laurent99/100
Packing: the desiccant sachet actually inside the secondary container. Documentation practice, not a single purity figure, is the substance here.
y.ndiaye98/100
Counter-ion identity and content answered quantitatively, one working day. Supplementary certificate produced without demur. No adverse observation.
o.novak98/100
Batch record supplied in full on request, attached rather than summarised. Desiccant enclosed within the secondary container.
l.nwosu97/100
Blind submission of CJC-1295 2 mg to Medutest, origin withheld. 99.5% against 99.2% declared.
b.abubakar95/100
Orthogonal identity present: mass spectrometry alongside the chromatographic determination. Reorder at 24 months within 0.1 points of the original. Contributor declares no interest beyond the transaction.
a.trevino96/100
Release signed and dated, named individual. Janoshik report held on file, figures match published.
i.demir98/100
Supplementary certificate for a lot released 18 months earlier retrieved from supplier records on request. Nothing unsecured in the consignment. Evidence base adequate for a rating on this criterion.
h.adebayo99/100
Retention time assigned to the principal peak, printed. Supplementary certificate produced without demur. Submitted to the index in full.
t.halvorsen96/100
Line quoted that three comparable suppliers declined to quote. Material returned within specification. No further comment.
j.kirchner97/100
Reconstitution of tesamorelin 2 mg: clear on contact, no haze, no particulate. Figures as reported by the named service. Not reproduced by the index.
jo.dahlberg99/100
Residual-solvent screen included unrequested. No adverse observation.
a.balogun95/100
Cross-check: Medutest and PeptideMeter, same lot, agreement to 0.1 points. Both agree with the declared figure. Identifier matches across vial, certificate and commercial documentation. Research use. Not approved for human administration.
r.kaufmann98/100
8 orders, 6 months. No substitution, no reformulation, no post-payment unavailability. Independent verification of individual lots still required.
ad.ibarra99/100
Cold chain intact. Phase-change pack solid at arrival, day 3. Supplementary certificate produced without demur. No further comment.
z.haddad98/100
Two lots ordered deliberately for comparison. Reported purities 0.1 points apart. Technical response inside four hours, working day. Figures as reported by the named service. Not reproduced by the index.
k.nascimento100/100
Lot-specific certificate in the parcel, not the batch-level summary. Related substances itemised with retention times.
as.kravchenko96/100
Related-substances table itemised by impurity with assigned retention times. Not aggregated. Price quoted per milligram of declared peptide content rather than per vial, which is the only comparison that survives a content figure. Submitted to the index in full.
g.beaulieu95/100
Published stock status matched availability. Same-day dispatch. Identifier matches across vial, certificate and commercial documentation. Independent verification of individual lots still required.
f.kuipers99/100
Single lot identifier across the whole consignment. Intra-consignment comparison valid. Record covers the lots named. Not generalised.
j.girard98/100
Certificate carries an itemised related-substances table. Complete against the index minimum data set at first issue. Supplementary certificate produced without demur. Documentation practice, not a single purity figure, is the substance here.
Block 12
Most recent records
Block 13
Contributor annotations on WWB records 797
Annotations are this index's only discussion surface: signed technical comments attached to a specific record by a named contributor. They are not moderated for agreement with the index's own arithmetic. The most recent on WWB material are below, each linked to the record it sits on.
Every named impurity on this record has a mass defect consistent with its structural assignment. That is the check that distinguishes an assignment from a guess.
Provenance and purity together are what make a figure like this usable. An independently purchased vial at 99.33 % is worth several supplier-selected ones.
One result at the top of the distribution should not move anybody's estimate much on its own. Purity distributions are compressed at the top and long-tailed at the bottom, so the informative observations are the low ones.
A high figure on one vial is a statement about one vial. The within-lot spread on the batch rollup is what tells you whether the bulk was well mixed, and it is the rarer and more useful number.
Core-shell packing at 2.6 µm gains roughly 40 % in resolution over a 5 µm fully porous bed at the same length and pressure. On a pair this close, that is the difference between two peaks and one.
Identity confirmed and purity at 99.52 %. The two answer different questions — what it is, and how much else is in it — and a record carrying both is the version worth citing.
Two decimal places on 99.52 % implies repeatability better than 0.01 pp, which no laboratory here claims. The number is sound; the printed precision is more than the method carries.
An orthogonal identity method on the same lot would make this the strongest class of record the index holds. Mass plus retention is already better than most.
Every annotation the index holds on WWB material sits on its own record; the full set is reachable from the record listing and from each contributor's page. To read them against what WWB itself publishes, open wuhanwanshengbio.com → alongside.
Block 14
Where to buy WWB
Wuhan Wansheng Biotechnology Co., Ltd. sells direct from wuhanwanshengbio.com. Everything on this page describes lots the index has already seen; the certificate that matters is the one that arrives with the vial you order, and the lot code on it should match the vial. Ask for the lot-specific document rather than the batch-level summary, and ask for the integration report if you intend to reconcile the figure yourself.
Go to the WWB store at wuhanwanshengbio.com →
Marked nofollow and sponsored. The index is paid nothing for it, takes no commission, and a link is not an assessment. Research compounds. Not medical advice. Nothing on this site is a safety assessment and nothing on it is approved for human use.